RecruitingNot ApplicableNCT05691439

Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep to Reward- and Stress-Related Brain Function

Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep Duration and Timing to Reward- and Stress-Related Brain Function


Sponsor

University of Oregon

Enrollment

150 participants

Start Date

Mar 27, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This research will use biobehavioral approaches to generate understanding about the linkages between sleep duration and timing, stressful life events, and depressive symptoms in adolescents, with a long-term aim of developing effective preventative interventions.


Eligibility

Min Age: 14 YearsMax Age: 18 Years

Inclusion Criteria6

  • years of age
  • Currently in high school
  • short and late sleep (weekday sleep duration ≤ 7 h and bedtime ≥ 22:30 (10:30 pm); n=100) or long and early sleep (weekday sleep duration \> 7 hours and bedtime ≤ 22:30 (10:30 pm); n=50), indexed by the Munich Chronotype Questionnaire
  • Lifetime stressful event frequency ≥ 2 on the Stress and Adversity Inventory (STRAIN) Screener
  • Depressive symptom severity t-score greater than or equal to 45 on the Patient Reported Outcomes (PROMIS) Depression scale
  • English language fluency

Exclusion Criteria15

  • Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for current moderate to severe alcohol/substance use disorder (≥4 symptoms);
  • Current clinician-provided diagnosis of narcolepsy or idiopathic hypersomnia;
  • Lifetime diagnosis of bipolar or schizophrenia spectrum disorder;
  • Certain medical conditions (e.g., serious neurological disorder, heart failure or serious heart trouble, history of head injury with unconsciousness \> 5 minutes);
  • Conditions that are contraindicated for magnetic resonance imaging (MRI; e.g., ferrous metal in the body);
  • Positive screen for participant-reported eye disease, epilepsy, or photosensitizing medications that are contraindicated during the manipulation condition when bright light is administered (e.g., psychiatric neuroleptic drugs \[e.g., phenothiazine\], psoralen drugs, antiarrhythmic drugs \[e.g., amiodarone\], antimalarial and antirheumatic drugs, porphyrin drugs used in photodynamic treatment of skin diseases);
  • Use of melatonin if participant is not willing to discontinue use for the duration of the study.
  • We will schedule around (i.e., delay appointments as needed) to avoid the timeframe of the following events:
  • urgent suicide risk, defined by moderate/severe risk per Columbia Suicide Severity Rating Scale (CSSRS) and clinician determination that current risk requires immediate action;
  • travel across two or more time zones within the month prior to the overnight study visits;
  • beginning or ending a prescribed medication within 2 months of the observational study;
  • prescribed medication dose changes within the timeframe calculated as 5x the drug's half-life \[the time to reach pharmacokinetic steady-state\] before the initiation of the observational or experimental studies;
  • anticipated change in prescribed medications or medication dosing during the observational or experimental studies;
  • current symptoms of airborne infectious illness prior to laboratory visits.
  • Participants with positive breathalyzer screen (blood alcohol level \> .02) will be rescheduled for an alternative overnight visit date.

Interventions

BEHAVIORALSleep extension and advance

Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses ("blue blockers") beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.

BEHAVIORALRegular sleep duration and timing

Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.


Locations(1)

University of Oregon

Eugene, Oregon, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05691439


Related Trials